Edgewise Therapeutics, Inc. EWTX
NASDAQ · United States · Health Technology
$40.60+1.41 (+3.60%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Edgewise Therapeutics (EWTX) could benefit from EDG-7500's differentiated drug profile, a potentiall
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that it will host an investor conference call to discuss the preclinical pharmacologic profile of EDG-7500, a first-in-class cardiac sarcomere modulator targeting the RLC. Data will be provided supporting EDG-7500's ability to improve cardiac relaxation while preserving overall systolic performance. Furthermore, early clinical observations in patients
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
UTHR, NMRA, and EWTX are drawing attention from options bears
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.